News and Announcements
Elixinol products launch in New Zealand following change in legislation
- Published January 23, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Elixinol products are now available to patients in New Zealand.
- The launch of products in new Zealand comes following the change in legislation which removes CBD as a Class B1 controlled drug.
- Patients may now import up to three months supply of CBD with prescriptions.
Elixinol Global Limited (ASX:EXL) is pleased to announce that Elixinol branded cannabidiol (CBD) products are now available on a prescription basis in New Zealand.
The launch of products in new Zealand comes following tthe passage of New Zealand’s Misuse of Drugs (Medicinal Cannabis) Amendment Act in December 2018, which classifies CBD with low levels of THC as prescription medicine and removes CBD as a Class B1 controlled drug.
The Act now recognises CBD as a substance with ‘therapeutic value with little or no psychoactive properties’.
Patients can now import up to three months worth of CBD products with a prescription.
Elixinol’s capsules, topicals and tinctures including liposomes meet the required standard for import into New Zealand.
Paul Benhaim, CEO of parent company EXL, said: ” Now, this change in New Zealand enables Elixinol to ship CBD to patients who have been requesting it for years.
We are delighted to be one of the first companies to supply New Zealand patients with the range our US customers have been benefiting from for years”.
About Elixinol Global Limited (ASX: EXL)
Elixinol Global Limited (ASX: EXL; OTCQX: ELLXF) through its businesses has a global presence in the cannabis industry including hemp-derived CBD dietary supplements, hemp food and wellness products, as well as cultivation and manufacture of medicinal cannabis products.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
